UPDATE 1-Rockwell Medical anemia drug fails efficacy goal
* Says drug meets safety goal
* Shares down 14 pct after market
Feb 25 (Reuters) - Biopharmaceutical company Rockwell Medical (RMTI.O) said its experimental drug to treat iron deficiency anemia in chronic hemodialysis patients failed to meet one of the main goals in a mid-stage study, sending its shares down 14 percent after the bell.
The company said its drug soluble ferric pyrophosphate (SFP) failed to meet the main efficacy goal due to the study design, but met the other primary safety endpoint.
The drug failed to show a decrease in hemoglobin of at least 1.0 g/d.
The study, however, met its objective of determining the dosing of SFP for the planned late-stage trials, the company said.
Rockwell Medical said the drug was well tolerated across the dose range studied, without evidence of toxicity.
Shares of the company were down $1.18 to $6.96 in after-market trade. They closed at $8.14 Thursday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Unnikrishnan Nair)
- Former WWE champ nabs suspected burglar in Arizona
- First Ebola victim in Sierra Leone capital on the run
- Thousands take to N.Y. streets to protest Israeli offensive in Gaza
- Apple iPhones allow extraction of deep personal data, researcher finds
- U.S. fighter jets escort Canadian plane home over passenger threat